Molecular Alterations in Partially-Encapsulated or Well-Circumscribed Follicular Variant of Papillary Thyroid Carcinoma

被引:83
作者
Howitt, Brooke E. [1 ]
Jia, Yonghui [2 ]
Sholl, Lynette M. [1 ,2 ]
Barletta, Justine A. [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Adv Mol Diagnost, Boston, MA 02115 USA
关键词
PAX8-PPAR-GAMMA REARRANGEMENT; INCREASING INCIDENCE; GENETIC ALTERATIONS; SIGNALING PATHWAYS; HIGH PREVALENCE; GROWTH-PATTERN; BRAF MUTATIONS; RAS MUTATIONS; UNITED-STATES; CANCER;
D O I
10.1089/thy.2013.0018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies have described an encapsulated and an infiltrative form of the follicular variant of papillary thyroid carcinoma (FVPTC). Encapsulated FVPTCs have been reported to have virtually no recurrence risk or metastatic potential and to harbor RAS mutations but not BRAF mutations. In contrast, infiltrative tumors have significant metastatic potential, a risk of recurrence, and a BRAF mutation frequency of approximately 25%. In our experience, a substantial number of FVPTCs are neither fully encapsulated nor infiltrative, but instead are partially encapsulated (PE) or well circumscribed (WC). We have previously reported that PE/WC FVPTCs behave in an indolent fashion similar to encapsulated tumors. The purpose of the current study was to evaluate the molecular alterations in PE/WC FVPTC. Methods: We identified 28 PE/WC FVPTCs resected consecutively at our institution. Targeted mutation analysis of 41 genes including members of the RAS and RAF families was performed on DNA extracted from formalin-fixed, paraffin-embedded blocks using single-base extension chemistry and mass spectrometry. Results: Lymph node metastases were absent in all cases with sampled lymph nodes, and no patients developed tumor recurrences (median follow-up time, 72.8 months). Overall, 13 cases (46%) harbored RAS mutations, including seven (25%) with NRAS mutations (p.Gln61Arg) and six (21%) with HRAS mutations (five had p.Gln61Arg and one had a p.Gln61Lys substitution). No PE/WC FVPTCs had BRAF mutations. Conclusions: The results of this study confirm our previous finding that PE/WC FVPTCs pursue an indolent clinical course. Additionally, we found that PE/WC tumors have a similar molecular profile to that of encapsulated FVPTCs with frequent RAS mutations (46%) and no BRAF mutations. These molecular results provide further evidence that PE/WC and encapsulated FVPTCs are biologically similar and should be distinguished from more aggressive infiltrative FVPTCs.
引用
收藏
页码:1256 / 1262
页数:7
相关论文
共 56 条
[1]   Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas [J].
Adeniran, AJ ;
Zhu, ZW ;
Gandhi, M ;
Steward, DL ;
Fidler, JP ;
Giordano, TJ ;
Biddinger, PW ;
Nikiforov, YE .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (02) :216-222
[2]  
Alexander C, 1998, J NUCL MED, V39, P1551
[3]   LATE SIDE EFFECTS OF RADIOACTIVE IODINE ON SALIVARY GLAND FUNCTION IN PATIENTS WITH THYROID CANCER [J].
Almeida, Juliana Pereira ;
Sanabria, Alvaro Enrique ;
Pereira Lima, Eduardo Nobrega ;
Kowalski, Luiz Paulo .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2011, 33 (05) :686-690
[4]   The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer [J].
Brown, Aaron. P. ;
Chen, Jergin ;
Hitchcock, Ying J. ;
Szabo, Aniko ;
Shrieve, Dennis C. ;
Tward, Jonathan. D. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02) :504-515
[5]  
CARCANGIU ML, 1985, CANCER-AM CANCER SOC, V55, P805, DOI 10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO
[6]  
2-Z
[7]   PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma [J].
Castro, P ;
Rebocho, AP ;
Soares, RJ ;
Magalhaes, J ;
Roque, L ;
Trovisco, V ;
de Castro, IV ;
Cardoso-de-Oliveira, M ;
Fonseca, E ;
Soares, P ;
Sobrinho-Simoes, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :213-220
[8]   Increasing Incidence of Differentiated Thyroid Cancer in the United States, 1988-2005 [J].
Chen, Amy Y. ;
Jemal, Ahmedin ;
Ward, Elizabeth M. .
CANCER, 2009, 115 (16) :3801-3807
[9]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[10]   WHAT IF MANY FOLLICULAR VARIANT PAPILLARY THYROID CARCINOMAS ARE NOT MALIGNANT? A REVIEW OF FOLLICULAR VARIANT PAPILLARY THYROID CARCINOMA AND A PROPOSAL FOR A NEW CLASSIFICATION [J].
Daniels, Gilbert H. .
ENDOCRINE PRACTICE, 2011, 17 (05) :768-787